Trevena, Inc. to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 22 2021 - 7:00AM
Trevena, Inc. (TRVN), a biopharmaceutical company focused on the
development and commercialization of novel medicines for patients
with central nervous system (CNS) disorders, today announced that
it will present a corporate update at the 10th Annual SVB Leerink
Global Healthcare Conference on Friday, February 26, 2021 at 8:40
a.m. EST.
Presentation Details |
Date: |
Friday, February 26, 2021 |
Time: |
8:40 a.m. Eastern Time |
Presenter: |
Bob Yoder, Senior Vice President and Chief Commercial Officer |
Webcast: |
https://wsw.com/webcast/svbleerink47/trvn/2707456 |
A link to the webcast will be available on the
Events page of the Investors section on the Company’s website at
www.trevena.com/investors/events-presentations/ir-calendar.
About Trevena
Trevena, Inc. is a biopharmaceutical company
focused on the development and commercialization of novel medicines
for patients with CNS disorders. The Company has one approved
product in the U.S., OLINVYK™ (oliceridine) injection, indicated in
adults for the management of acute pain severe enough to require an
intravenous opioid analgesic and for whom alternative treatments
are inadequate. The Company also has four novel and differentiated
investigational drug candidates: TRV250 for the acute treatment of
migraine, TRV734 for maintenance treatment of opioid use disorder,
and TRV027 for acute lung injury / abnormal blood clotting in
COVID-19 patients. The Company has also identified TRV045, a novel
S1P receptor modulator that may offer a new, non-opioid approach to
treating a variety of CNS disorders.
For more information, please
visit www.Trevena.com.
Investor Contact:Daniel
FerryLifeSci AdvisorsPhone: 617-430-7576Email: IR@trevena.com
Company Contact:Bob Yoder, SVP
and Chief Commercial OfficerTrevena, Inc.Phone: 610-354-8840
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Sep 2023 to Sep 2024